TD Cowen raises Kiniksa stock price target on Arcalyst growth By Investing.com

TD Cowen raised Kiniksa Pharmaceuticals’ price target to $65 from $60 and kept a Buy rating after Arcalyst Q1 2026 sales reached $214 million, up 6% sequentially and 56% year over year. The quarter beat consensus by 5%, and the firm lifted its peak sales estimate for recurrent pericarditis to $2.3 billion. Kiniksa also reported Q1 EPS of $0.27 versus $0.21 expected and revenue of $214.3 million versus $207.12 million consensus.

Analysis

KNSA is shifting from a single-asset commercialization story to a self-funded durability story. The key second-order effect is that a stronger-than-expected launch reduces the probability of future dilutive financing and makes the equity behave less like a binary biotech and more like a mid-cap specialty pharma with visible terminal value. That rerating matters because once investors stop underwriting capital raises, the multiple can expand faster than the revenue base.

The bigger market implication is competitive, not just company-specific: if recurrent pericarditis continues to outperform, it raises the bar for every adjacent orphan/inflammation asset trying to win physician mindshare with less differentiated efficacy or weaker convenience. It also likely compresses the window for would-be challengers, because payers are more tolerant of premium pricing when the incumbent is already embedded and expanding. In practical terms, the franchise becomes harder to dislodge the longer it compounds above consensus.

The main risk is that the current move may be too linear. The stock has already absorbed a good portion of the launch acceleration, so the next leg likely depends on either a major estimate reset or proof that growth persists beyond the typical seasonal and channel-fill noise. Over the next 3-6 months, the key reversal trigger is not one bad quarter, but any evidence that growth is decelerating faster than the market can re-rate the DCF assumption set.

The contrarian view is that investors may be overpaying for peak-sales credibility before KPL-387 data de-risks the second act. If the pipeline disappoints, KNSA could revert to being valued mostly on Arcalyst cash flow, which is strong but not necessarily enough to justify an evergreen growth multiple. That creates a classic setup where upside is easier in the near term than over a 12-24 month horizon unless pipeline optionality starts converting into probability-adjusted value.

Key Decisions for Investors

• Stay long KNSA into the next 1-2 quarters, but size it as a cash-flow rerating trade rather than a pure biotech catalyst trade; upside remains attractive if sell-side estimates continue to move, but the stock is now more sensitive to growth durability than beat/miss volatility.
• Buy KNSA call spreads 3-6 months out to express upside from continued Arcalyst momentum while capping premium paid; this is the cleanest way to participate if the market keeps migrating the name toward specialty-pharma multiples.
• For a relative-value expression, long KNSA / short a slower-growing specialty pharma peer with similar EV/revenue but weaker balance-sheet support; the trade benefits if investors keep rewarding self-funded growth and penalizing names dependent on external capital.
• Take profits on a portion of longs on any sharp post-earnings re-rating; the risk/reward worsens after a DCF-driven target lift if the next catalyst is still months away and the multiple has already anticipated a lot of the upside.
• Monitor KPL-387 as a medium-term binary: if phase II data is strong in 2H26, add on pullbacks; if it underwhelms, expect the stock to trade back toward a cash-flow-only framework with limited multiple expansion.